• Development and validation of PBPK models for predicting in vivo CNS exposure, distribution, and cellular engagement
• Characterizing cell-type–specific targeting in the CNS through consideration of biological barriers, cellular diversity, and molecular design
• Bridging preclinical insights to clinical application and identifying gaps  

NEW DATA